Chronic obstructive pulmonary disease (COPD) is a prevalent, preventable, and treatable heterogeneous lung disease characterized by persistent, often progressive airflow obstruction resulting from abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema). It manifests chronic respiratory symptoms such as dyspnea, cough, expectoration, along with wheezing, chest tightness, fatigue, and reduced activity levels. Some patients may also experience acute exacerbations characterized by increased respiratory symptoms, which can impact their physical condition and prognosis, necessitating specific prevention and therapeutic measures1.
According to the Global Burden of Disease Study by the World Health Organization (WHO) and the Burden of Obstructive Lung Diseases (BOLD) project, the prevalence of COPD worldwide is 10.3%, leading to approximately 3 million deaths annually, making COPD the third leading cause of mortality globally2,3,4. In China, data from a nationwide cross-sectional study indicates an 8.6% prevalence of COPD, with a striking 13.7% prevalence among people over 40 years old. A considerable proportion of patients have not received timely diagnosis and treatment, which severely impacts public health5.
With the increase in smoking rates in low- and middle-income countries and the exacerbation of population aging in high-income countries, the burden of COPD is anticipated to escalate. Estimates suggest that by 2060, COPD and related diseases will claim the lives of more than 5.4 million people annually, resulting in significant economic and social burdens, including direct and indirect treatment costs. Similarly, productivity loss and premature retirement caused by the disease are also considered the main sources of indirect costs of the disease6,7.
An acute exacerbation of COPD (AECOPD) is defined as a transient worsening of dyspnea, cough, and expectoration production lasting less than 14 days, often triggered by local and systemic inflammation caused by airway infection, pollution, or other lung injuries8. A population-based survey conducted in nine Asia-Pacific regions showed that 46% of patients with COPD had at least one acute exacerbation in the previous year, and 19% of patients required hospitalization9.
It is worth noting that COPD has imposed considerable costs on the healthcare system, mainly related to the moderate to severe stage and complications. A systematic review of COPD cost analysis reveals that AECOPD treatment costs significantly contribute to overall treatment expenses7. Current management strategies for acute exacerbations involve pharmacological and non-pharmacological interventions aimed at alleviating airway obstruction, combating infections, and enhancing oxygenation. However, they are still facing challenges like rising drug resistance and airway microbiome disturbances10.
Cupping therapy is an ancient traditional Chinese medicine technique with a history spanning thousands of years. Much like acupuncture, it is an essential component of complementary and alternative medicine worldwide11. Cupping therapy is a non-pharmacological external treatment method that uses plastic, bamboo, or glass cups as tools. By utilizing methods such as burning, suction, or steam to create negative pressure within the cup, the cups are able to adsorb onto specific points on the body's surface, acupoints, or meridians, which can stimulate subcutaneous tissues, promoting congestion and blood stasis in the local skin, thereby achieving the goal of preventing and treating diseases12. Moving cupping along meridians is a branch of the cupping method based on the meridian theory of acupuncture and moxibustion. Through the application of flame, the cup adheres to the skin, and with the aid of glycerin, it repeatedly moves along the pathways of the meridians, resulting in benign stimulation13.
This article elaborates on the operation steps, key points, and precautions of moving cupping along meridian therapy for AECOPD, including patient qualification assessment, medical equipment used, treatment site, course of treatment, posttreatment care, and adverse reaction response measures. The study employed the medical outcomes study 36-item short form (SF-36) health survey questionnaire, the modified Medical Research Council dyspnea scale (mMRC), and the COPD Assessment Test (CAT) score as efficacy evaluation indicators. The efficacy of this protocol can be assessed by comparing the scores of patients before and after treatment. With the advantages of definite curative effect, low cost, and easy acceptance by middle-aged and elderly patients, moving cupping along meridians therapy shows the potential to offer a new direction for non-pharmacological treatment of AECOPD.